InspireMD, Inc. (NSPR) AI Stock Analysis

InspireMD, Inc. operates as a medical device company focused on the development and commercialization of its proprietary MicroNet stent platform technology. Designed primarily for treating vascular and coronary diseases, the company's solutions are distributed across Europe, Latin America, the Middle East, and the Asia Pacific regions. Its product portfolio features the CGuard carotid embolic prevention system and MGuard Prime embolic protection systems, which target acute coronary syndromes including acute myocardial infarction and bypass surgery interventions. In addition, InspireMD is developing PVGuard for peripheral vascular treatments. The company commercializes its products globally through a network of local distributors.

Revenue increased from $4.5M in FY2021 to $9.0M in FY2025, generating a 5-year revenue CAGR of 29.3%. Annual revenue grew 28.1% in FY2025, improving from 13.0% in FY2024 and 20.0% in FY2023. Gross margin rose to 29.5% in FY2025 from 16.8% in FY2021. However, operating margin worsened from -327.4% in FY2021 to -547.0% in FY2025 as research and development spending expanded to $15.0M. Net loss widened from -$14.9M in FY2021 to -$48.8M in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $10.8M, with quarterly revenue falling 0.4% year-over-year.

As of June 30, 2026, InspireMD reported $30.4M in cash and short-term investments and $2.0M in total debt, providing a net cash position of $28.5M. Total assets were $44.6M and shareholders' equity was $31.5M. The company maintains a current ratio of 3.80 and a debt-to-equity ratio of 0.06. In FY2025, operating cash flow was -$35.1M and free cash flow was -$36.8M, with capital expenditures of $1.7M. The company's share count increased 842.4% over a 5-year period.

At a last close of $0.46, InspireMD has a market capitalization of $21.2M and an enterprise value of $7.8M. The stock trades at a price-to-sales ratio of 2.0x, below the 4.1x median of its US-listed Healthcare peers. Its forward price-to-earnings multiple is 11.7x compared to the peer median of 17.3x, and its enterprise value-to-EBITDA is 0.5x versus the peer median of 12.0x. Over the past year, NSPR shares fell 80.7% while the S&P 500 gained 16.8%. Over five years, the stock fell 89.2% compared to an 83.0% gain for the benchmark.

InspireMD has 1 Strong Buy, 2 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings from analysts. The mean price target of $3.33 represents an upside of 624.6% relative to the last close of $0.46. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $9.8M and an EPS of -$0.45. For the next fiscal year, 3 analysts project revenue of $20.1M, representing revenue growth of 105.4%, and an EPS of -$0.48. The company beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of InspireMD, Inc. (NSPR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NSPR income statement, NSPR balance sheet, NSPR key metrics, NSPR analyst forecast, NSPR chart. See the NSPR stock overview for the latest quote and news.